Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab, Anlotinib, and SBRT for NSCLC Brain Metastases
NCT05021328Phase 1Completed
- Sponsor
- Hubei Cancer Hospital
- Start
- Oct 2021
- Primary completion
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of toripalimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Hubei Cancer Hospital. Primary endpoints: Treatment-related adverse events at 24 months and Intracranial response rate at 4 weeks. Started Oct 2021; status: completed.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05021328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05021328.